ASCO GI 2024 | REGONEXT: 2L regorafenib in patients with unresectable HCC who have progressed on atezo-bev

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Korea, discusses results from a Phase II investigator-initiated trial conducted in Korea which aimed to assess the efficacy and safety of second-line regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) who experienced progression on first-line atezolizumab-bevacizumab (atezo-bev) treatment. Results indicated a median progression-free survival (PFS) of 3.5 months, with an objective response rate (ORR) of 10.0% and a disease control rate (DCR) of 82.5%. Adverse events were manageable. The study supports regorafenib as a viable second-line therapy for uHCC after atezolizumab-bevacizumab failure. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.